Galderma, a Swiss pharmaceutical company known for its skin care treatments, is seizing an opportunity in the growing popularity of weight-loss drugs like Ozempic. The CEO believes that the sunken-in look that some patients experience with Ozempic could lead to an increase in demand for their facial fillers products.
Galderma has already started a study to evaluate the effects of Sculptra and Restylane for cheek augmentation and contour deficiencies in patients using GLP-1 treatments. Enrollment is ongoing, and results may be available by the end of the year. This study aims to capitalize on the trend of weight-loss drugs like Ozempic by providing patients with solutions to counteract the sunken look associated with rapid weight loss.
The term “Ozempic face” has become increasingly common among dermatologists due to the widespread use of weight-loss medications. It refers to the sunken and aged appearance that can result from rapid weight loss. However, Galderma’s fillers can help restore this gaunt look, making it an attractive option for those looking to combat the effects of weight loss on their face.
Galderma went public last month on the SIX Swiss Exchange and reported a 12.4% increase in sales year-over-year in the first quarter of the year. The company also owns popular drug store brand Cetaphil. The CEO remains optimistic about the growth potential in the fillers market and plans to capitalize on this trend by offering solutions like Sculptra and Restylane for patients using GLP-1 treatments.
Overall, Galderma’s focus on capitalizing on trends in health and wellness makes it a promising investment opportunity for those looking for companies that are at the forefront of innovation in this space.